

COVID-19 Deaths
Compared to
Cardiac Deaths

Cardiac Deaths: 2012	49
Cardiac Deaths: 2013	39
Cardiac Deaths: 2014	65
Cardiac Deaths: 2015	60
Cardiac Deaths: 2016	44
Cardiac Deaths: 2017	53
Cardiac Deaths: 2018	38
Cardiac Deaths: 2019	36

COVID Deaths 2020 - 2021...



"If we had seen this many firefighters killed by any other cause, there would be no question about whether a **Stand Down was** necessary"



Dr. James Augustine

Medical Director for Fire/EMS agencies in Atlanta, Georgia; Naples, Florida; and Dayton, Ohio

Medical expert for the IAFC COVID Task Force

Serves the IAFF in infection control efforts

JAMA Health Forum.

Incidence of SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential Workers During a Prevaccination COVID-19 Surge in Arizona

Katherine D. Ellingson, PhD; Joe K. Gerald, MD, PhD, Xiaoxiao Sun, PhD; James Holkster, BS; Karen Lutrick, PhD; Joel Parker, MS; Patrick Rivers, MPP, Shawn C. Beitel, MS; Zoe Baccam, BS; Julie Mayo Lamberte, MSP4; Lauren Grant, MS; Elizabeth Kim, MSP4; Rachana Bhattarai, BVSc&AH, MS; PhD; Deep Rivers, MPP, Rachana Bhattarai, BVSc&AH, MS; PhD; Deep Rivers, MPP, PhD; Deep Rivers, MS; PhD; Deep R Katherine D, Ellingson, PhD, Joe K, Gerald, MD, PhD, Xiaoxiao Sun, PhD: James Hollister, BS: Karen Lutrick, PhD: Joel Parker, MS: Patrick Rivers, MPP: James Hollister, BS: Karen Lutrick, PhD: Joel Parker, MS: Patrick Rivers, MPP: Menneth Komatsu, MPH: Jernafer Meece, PhD: Preeta K, Kuttv, MD, MPH: Mark G. Thompson, PhD: Jefferey L. Burgess, MD: MS, PhD: Jefferey L. Burgess, MD: MS, MPH: MS, PhD: Jefferey L. Burgess, MD: MS, PhD: Jefferey L. Burgess, MD Shawn C. Beitel, MS; Zoe Baccam, BS; Julie Mayo Lamberte, MSPH: Lauren Grant, MS; Elizabeth Kim, MSPH: Rachana Bhattarai, BVSc&A; Kenneth Komatsu, MPH; Jennifer Meece, PhD; Preeta K. Kutty; MD, MPH; Mark G. Thompson, PhD; Jefferey L. Burgess, MD, MS, MPH

IMPORTANCE Understanding the relative risk of SARS-CoV-2 infection across occupations can inform guidance to protect workers and communities. Less is known about infection risk for first

OBJECTIVE To compare the prevaccination incidence of SARS-Cov2 infection among first responders and other essential workers with incidence among health care personnel.

DESIGN, SETTING, AND PARTICIPANTS This was a prospective cohort study of health care DESIGN, SETTING, AND PARTICIPARTS INS Was a prospective conort study of nearth care personnel, first responders, and other essential workers in Arizona from July 20, 2020, to March 14, worked at least 20 hours per week, and submitted weekly nasal swab specimens for real-time worked at reast 20 nours per week, and submitted weekly hasar swad specifiers for real-time reverse transcriptase polymerase chain reaction analysis. Data analyses were performed from April

EXPOSURES Occupation was the primary exposure of interest. Confounders assessed were **EXPUSURES.** Occupation was the primary exposure or interest. Lonrounders assessed were sociodernographic characteristics, health status, community exposure, and work exposure.

MAIN OUTCOMES AND MEASURES Crude incidence of SARS-CoV-2 infection was defined as the MAIN UUI LUNES AND MEASURES Crude incidence of SARS-CoV-2 infection was defined as the SARS-CoV-2 infections in participants divided by person-weeks at risk. Negative sum or first positive SANS-CoV-2 infections in participants curvated by person-vietes at 175th frequence binomial regression was used to model SARS-CoV-2 infection by occupation to estimate unadjusted binomial regression was used to made such a core interchally occupation to estimate or any occupanion to estimate or any occupanion to estimate or any occupanion of the core (LASSO) method was used to generate a parsimonious multivariable model.

RESULTS The study conort comprised I/ob Arizona workers (mean age (201), 43.5 (11.11) years; 10.9 [61,9%] female; 401 [22,7%] were Hispanic and 1530 [86,6%] were White individuals) of whom essential workers, respectively. In unadjusted models, first responders had twice the including infection as health care personnel (IRRs, 2.0); 95% CI, 1.44-2.79). While attenuated, this risk Intection as nealth care personnel (IRRS, Z.UI; 35% U, 1.44-Z./3), While attenuated, URS 135K effective and adjusted LASSO-optimized models (IRR, 1.60; 95% Cl, 1.07-2.38). Risk of femainea elevatea in agiustea LASSU-optimizea modeis (IRIK, LIGU; 2000 CL, LUTZ-20), NISK (IRIK) namong other essential Workers was no different than for health care personnel in

CONCLUSIONS AND RELEVANCE This prospective cohort study found that first responders had a CONCLUSIONS AND RELEVANCE This prospective conort study found that first responders had higher incidence of SARS-CoV-2 infection than health care personnel, even after adjusting for

JAMA Health Forum: 2021;2(10):e213318. doi:101001/jamahealthforum:2021;3318

Question Before COVID-19 vaccine availability, how comparable were rates

incidence of SARS-CoV-2 infection than

given their higher rates of SARS-CoV-2

Author affiliations and article information are listed at the end of this article.

WHAT IS THE RISK TO FIRE & EMS?

Firefighters are 60-100% more likely to contract **COVID-19 than** other HEALTH **CARE WORKERS**



Among those who have not been vaccinated, an estimated 10% of firefighters are experiencing Long COVID – often leading to disability.

Long COVID is when symptoms last more than 4 weeks


The range of long-term symptoms vary significantly and can include:

- Persistent cough
- Shortness of breath
- Fatigue
- Headache
- Heart palpitations
- Chest pain
- Physical limitations
- Depression
- Insomnia



What's The Issue with Vaccines For Fire & EMS?

- Is the vaccine safe?
- Is it a vaccine?
- How does it work?
- If I'm healthy, do I need it?




WERE VACCINES DEVELOPED AND BROUGHT TO MARKET TOO QUICKLY TO BE SAFE?

The speed of the vaccines coming to market can be attributed to:

- Existing scientific advances on mRNA and other types of coronavirus vaccines
- Expedited funding
- Fast study recruitment
- Highly effective vaccine and rapid spread of disease
- Expedited review

Figure 2. Cumulative Incidence Curves for the First COVID-19 Occurrence After Dose 1, Dose 1 All-Available Efficacy Population



HOW MANY DOSES OF VACCINE WILL BE NEEDED?



The ultimate number of doses remains a question

Recommendations will be made as data dictates based on careful monitoring of immunity

It is not uncommon for series of vaccines to be necessary for long term immunity

Currently, it is recommended that first responders, who are classified as a "high risk" occupation, receive a "booster" shot

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html

How likely is that there will be long term side effects to the COVID-19 vaccine that just aren't identified yet

- Side effects typically occur within the first 72 hours post vaccination
- Nearly every vaccine side effect (for COVID vaccines and all others) occur within the first 2 months post vaccination
- Vaccines leave the body within 72 hours
- No long-term buildup of vaccines



Is Anyone Paying Attention To The Side Effects Of The Vaccine?














Moderna = 5.9% of total

Pfizer = 3.8% of total

Percentage of fire fighters who, after their second shot, experienced side-effects other than arm pain AND whose symptoms lasted more than 2 days*


*based on survey of nearly 12,000 firefighters throughout North America





Moderna = 5.2% of total

Pfizer = 4.3% of total



Over 97% of fire fighters, regardless of vaccine type, recommend others get the vaccine

C CFREHR 2021


What is Myocarditis?


 Myocarditis is inflammation of the heart muscle, or myocardium, that can result in hospitalization, heart failure, and sudden death.

 Common symptoms include shortness of breath, chest pain, feelings of fastbeating/fluttering/pounding heart.

 Myocarditis is a rare disease (4-6 cases/100,000), usually (50-70% of cases) caused by viral infections, and most common among young adult males.

 Concerns have emerged about the development of myocarditis after the receipt of mRNA vaccines – typically among young adult males after the second dose with symptoms occurring several days post vaccine.





Myocarditis after Vaccine vs. Infection

- Across all age groups, the relative risk of myocarditis is about 16 times higher for people with COVID-19 compared to those who are not infected
- A large study published in the New England Journal of Medicine found that myocarditis risk was 6 time higher after COVID-19 infection than after vaccination
- Among the more than 2.5 million vaccinated people in studies who were 16 years or older, 54 met the criteria for myocarditis. Most cases (about three quarters) were mild and another 22% were moderate
- It is important to note that although the rate of myocarditis is higher among COVID-19 infected individuals, it is still a rare disease in both groups



Is it really considered a vaccine if people can still get COVID-19?

SHORT ANSWER: "Yes."

LONG ANSWER: Vaccines are designed to prevent infection or decrease symptoms when someone is infected because the immune system has learned from the vaccine how to fight the virus.

COVID-19 VACCINES vs. OTHER VACCINES

Polio vaccine – 2 doses 90%, 3 doses 99%, 4 doses just under 100%

MMR (measles, mumps, rubella) – 1 dose 93%, 2 doses 97%

Flu – prevents 40-60% of infection

Moderna – Pre-Delta, 91% (100 days after second dose);

Delta 70% (250 days after second dose) in preventing

symptomatic COVID-19

Pre Delta, 94%; Delta 92% effective in preventing hospitalization

67-90% reduction in transmission of COVID-19

Pfizer – Pre-Delta, 80% (100 days after second dose);

Delta 65% (250 days after second dose) in preventing

symptomatic COVID-19

Pre-Delta, 95%; Delta 78% (5 months after full vaccination) in

preventing hospitalization

72-95% reduction in transmission of COVID-19

Johnson &

Johnson – Pre-Delta, 68%;

Delta 49-78% in preventing symptomatic COVID-19


Pre-Delta, 100% in clinical trials;

Delta, 60-81% in preventing hospitalization 74% reduction in transmission of COVID-19

HOW DO COVID VACCINES COMPARE TO OTHER VACCINES?

WHAT IS THE BENEFIT OF GETTING THE VACCINE?

Weekly trends in age-standardized incidence* of COVID-19 cases, hospitalizations, and deaths, by vaccination status: April 4–July 17, 2021




• Rates are standardized by age, according to the enumerated 2000 U.S. Census age distribution. Blue vertical lines indicate when the B.1.617.2 (Delta) variant reached a threshold of >50%, using weighted estimates for 13 jurisdictions combined.

IF MY IMMUNE SYSTEM IS IN GOOD SHAPE, DO I REALLY NEED A VACCINE?

WON'T MY BODY JUST FIGHT IT OFF?

- Risk of severe disease is higher for those who are less healthy
- However, those who are healthy can still have severe, negative side effects
- Vaccines reduce spread of infection
- High community spread leads to faster mutations



Although COVID-19 is typically mild in young people, about 30% of youth hospitalized with COVID-19 have no underlying health conditions that would have put them at increased risk.

Amid the recent delta surge, hospitalization rates were about 10 times higher in unvaccinated young people than vaccinated ones.

Are the treatment approaches so good that you don't need to worry about getting sick?






WHAT ABOUT IVERMECTIN?

"Overall, the reliable evidence available does not support the use of Ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials."



DO YOU STILL **BENEFIT FROM A VACCINE IF YOU HAVE ALREADY** HAD **COVID-19?**









NEED MORE INFORMATION?

If you still have questions, we are happy to help answer them

Send questions to:
Chief Scott Kerwood,
Chair, Safety, Health & Survival Section, IAFC sdkerwood@huttofirerescue.org

Developed by:



THANK YOU

This project was supported in part by the following organizations:



